Redesigning digital health go-to-market models to align with drug commercialisation models
Redefining Market Strategies: Digital Health Meets Pharma
Discover how aligning digital health go-to-market (GTM) models with traditional drug commercialisation strategies can revolutionise market success. Our latest report, Redesigning digital health go-to-market models to align with drug commercialisation models, explores the strategic integration of digital health and pharmaceutical commercialisation, covering market segmentation, value demonstration, regulatory strategy, pricing, reimbursement, and more
Insights from leading industry experts highlight the challenges and solutions of a commercial redesign, offering a roadmap for enhanced market success and stakeholder engagement.
Companies
GSK, AstraZeneca, Sanofi, Pfizer, Biogen, Johnson & Johnson Innovative Medicine, Merck Group, LucidQuest, Wavestone, Evinova
Subject synopsis
Research methodology and objectives
Key insights summary
Issues and insights
The value of aligning digital health GTM models with drug commercialisation models